Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Do Not Discard
Interestingly, GLP-1 RAs showed a favorable safety profile in IBD patients, exhibiting comparable tolerability to non-IBD populations
This cutting-edge method delivers safe, natural, and powerful fat reduction
eligible Medicare patients can access FDA-approved GLP-1 medications for $50/month through the CMS Medicare GLP-1 Bridge Program - a different pathway worth evaluating before enrolling in a cash-pay compounded program FDA adverse event data (as of May 21, 2026): FDA had received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide combined - a safety signal not specific to Omzo but material context for any compounded GLP-1 enrollment decision
Many patients taking tirzepatide use other medications that can cause or worsen ED, including: Beta-blockers (especially non-selective agents) and thiazide diuretics Selective serotonin reuptake inhibitors (SSRIs) and antipsychotics 5-alpha reductase inhibitors (finasteride, dutasteride) Opioids, spironolactone, clonidine, and cimetidine Other medical conditions such as obstructive sleep apnea and hypogonadism (testosterone deficiency) are common in patients with diabetes and obesity and independently contribute to ED
